2. Search Result
Search Result
Pathways Recommended: PI3K/Akt/mTOR
Results for "

K

" in MedChemExpress (MCE) Product Catalog:

2411

Inhibitors & Agonists

20

Screening Libraries

27

Fluorescent Dye

28

Biochemical Assay Reagents

174

Peptides

3

MCE Kits

21

Inhibitory Antibodies

369

Natural
Products

256

Recombinant Proteins

94

Isotope-Labeled Compounds

133

Antibodies

7

Click Chemistry

112

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0254
    Glipizide

    CP 28720; K 4024

    		 Potassium Channel Metabolic Disease Cancer
    Glipizide (CP 2872; K 4024)?a potent, orally active and sulfonylurea class anti-diabetic agent and can be used for type 2?diabetes mellitus research but not type 1. Glipizide acts by partially blocking ATP-sensitive potassium?(KATP) channels among β cells of pancreatic islets of Langerhans .
    Glipizide
  • HY-12743A
    K-7174 dihydrochloride
    10+ Cited Publications

    		 Proteasome Apoptosis Inflammation/Immunology Cancer
    K-7174 dihydrochloride is an orally active proteasome and GATA inhibitor. K-7174 dihydrochloride is a cell adhesion inhibitor. K-7174 dihydrochloride induces cell apoptosis. K-7174 dihydrochloride shows antitumor activities, it can be used for the research of cancer .
    K-7174 dihydrochloride
  • HY-12743
    K-7174
    10+ Cited Publications

    		 Proteasome Apoptosis Inflammation/Immunology Cancer
    K-7174 is an orally active proteasome and GATA inhibitor. K-7174 is a cell adhesion inhibitor. K-7174 induces cell apoptosis. K-7174 shows antitumor activities, it can be used for the research of cancer .
    K-7174
  • HY-14533
    K 01-162

    K162

    		 Amyloid-β Neurological Disease
    K 01-162 (K162) inhibits the fibril formation of Aβ peptides and eliminates their neurotoxicity. K 01-162 binds with Aβ42 peptide with an EC50 value of 80 nM. K 01-162 binds directly to AβO with a KD value of 19 μM. K 01-162 is capable of penetrating the brain and can be used for the research of Alzheimer’s disease .
    K 01-162
  • HY-121435
    K-8012

    		RAR/RXR PI3K Akt Apoptosis Cancer
    K-8012, a sulindac (HY-B0008) analog, is a potent antagonist of RXRa. The IC50 value for K-8012 to inhibit 9-cis-RA-induced Gal4-RXRa-LBD trans-activation were about 9.2 μM. K-8012 exerts improved anticancer activity over sulindac in a RXRa-dependent manner. K-8012 exhibits activity in inhibiting the tRXRa-mediated PI3K/AKT signaling pathway. K-8012 induces apoptosis and inhibits AKT activation by preventing tRXRa from binding to p85a .
    K-8012
  • HY-138565
    K-975
    20+ Cited Publications

    		 YAP Cancer
    K-975 is a potent, selective and orally active TEAD inhibitor, with a strong inhibitory effect against protein-protein interactions between YAP1/TAZ and TEAD. K-975 covalently binds to Cys359 located in the palmitate-binding pocket of TEAD via an acrylamide structure. K-975 exhibits antitumor activity on malignant pleural mesothelioma .
    K-975
  • HY-136943
    K-41

    		Antibiotic Parasite Bacterial Infection
    K-41 is an orally active antibiotic. K-41 can be obtained from Streptomyces hygroscopicus. K-41 has antibacterial and antiplasmodial activity .
    K-41
  • HY-111214
    K-14585

    		Protease Activated Receptor (PAR) NF-κB p38 MAPK Inflammation/Immunology
    K-14585 is a peptide competitive PAR2 antagonist. K-14585 inhibits PAR2-dependent IL-8 production, NF-κB phosphorylation, and p38 signaling. K-14585 reduces SLIGKV (PAR2 agonist peptide)-induced Ca 2+ mobilisation in primary human keratinocytes .
    K-14585
  • HY-P5704
    K11

    		Bacterial Infection
    K11 is an antimicrobial peptide. K11 is active against MDR/XDR K. pneumoniae isolates (MIC: 8-512 μg/mL), and inhibits bacterial biofilm formation. K11 can act synergistically with antibiotics (Chloramphenicol (HY-B0239), Meropenem (HY-13678), Rifampicin (HY-B0272), etc.) against drug-resistant K. pneumoniae. K11 has high thermal and wide pH stability .
    K11
  • HY-168893
    K882

    		Src Apoptosis IAP Survivin Akt mTOR JAK STAT Ras p38 MAPK Cancer
    K882 (Compound 4e) is a Src inhibitor, with KD of 0.315 μM. K882 induces Apoptosis. K882 inhibits XIAP and Survivin. K882 inhibits the activation of PI3K/Akt/mTOR, Jak1/Stat3, Ras/MAPK signaling pathways. K882 shows anti-tumor activity against non-small cell lung cancer .
    K882
  • HY-121681
    K 308

    		Others Inflammation/Immunology
    K 308 is a non-steroid antiinflammatory agent .
    K 308
  • HY-123141
    K00135

    		Pim Cancer
    K00135 is a potent and selective inhibitor of PIM kinases. K00135 inhibits survival and clonogenic growth of acute leukemia cells. K00135 inhibits the phosphorylation of PIM downstream targets .
    K00135
  • HY-103433
    K579

    		Dipeptidyl Peptidase Metabolic Disease
    K579 is a potent and orally active dipeptidyl peptidase IV inhibitor. K579 inhibits the blood glucose elevation. K579 increases the plasma insulin and active forms of glucagon-like peptide-1 (GLP-1). K579 has the potential for the research of diabetic .
    K579
  • HY-113852
    K-259-2

    		Others Others
    K-259-2 is an active compound.
    K-259-2
  • HY-P10556
    (KFF)3K

    		Bacterial Infection
    (KFF)3K is a cell penetrating peptide that can promote the absorption of other antibiotics by disrupting the outer membrane of bacteria. (KFF)3K can be introduced into a hydrocarbon scaffold to induce its antibacterial properties, making it an effective antimicrobial peptide. (KFF)3K can be used in the development of new antimicrobial agents .
    (KFF)3K
  • HY-161622
    K1586

    		Checkpoint Kinase (Chk) Cancer
    K1586 is an amidine derivative that efficiently targets Chk1. K1586 enhances the degradation of Chk1 that sensitizes colorectal cancer cells to ionizing radiation. K1586 shows anticancer effects .
    K1586
  • HY-N6736
    K-252c

    		Beta-lactamase PKC Bacterial Apoptosis Infection Cancer
    K-252c, a staurosporine analog isolated from Nocardiopsis sp., is a cell-permeable PKC inhibitor, with an IC50 of 2.45 µM. K-252c induces apoptosis in human chronic myelogenous leukemia cancer cells. K-252c also inhibits β-lactamase, chymotrypsin, and malate dehydrogenase .
    K-252c
  • HY-P990534
    Anti-TSHR Antibody (K1-70)

    K1-70

    		 TSH Receptor Inflammation/Immunology
    Anti-TSHR Antibody (K1-70) is a CHO-expressed human antibody that targets TSHR. Anti-TSHR Antibody (K1-70) has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 143.54 kDa. For the isotype control of Anti-TSHR Antibody (K1-70), you can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-TSHR Antibody (K1-70)
  • HY-146959
    K203

    		Cholinesterase (ChE) Neurological Disease
    K203 is a potent reactivator of tabun-inhibited AChE. K203 is a crucial antidote used for the organophosphate intoxication .
    K203
  • HY-157658
    K-8794

    		Endothelin Receptor Cardiovascular Disease
    K-8794 is an orally active selective endothelin receptor ETB antagonist that can be used in research on cardiovascular diseases .
    K-8794
  • HY-144762
    K027

    		Cholinesterase (ChE) Neurological Disease
    K027 is a potent reactivator of Organophosphates (OP)-inhibited acetylcholinesterase (AChE). K027 can be used for the research of Alzheimer's disease .
    K027
  • HY-119293A
    K777 tosylate

    		Cathepsin CCR Cytochrome P450 Parasite SARS-CoV Filovirus Infection Cancer
    K777 tosylate is a potent, orally active and irreversible cysteine protease inhibitor. K777 tosylate is also a potent CYP3A4 inhibitor with an IC50 of 60 nM and a selective CCR4 antagonist featuring the potent chemotaxis inhibition. K777 tosylate irreversibly inhibits Cruzain, the major cysteine protease of Trypansoma cruzi, and cathepsins B and L. K777 tosylate is a broad-spectrum antiviral by targeting cathepsin-mediated cell entry. K777 tosylate inhibits SARS-CoV and EBOV pseudovirus entry with IC50 values of 0.68 nM and 0.87 nM, respectively .
    K777 tosylate
  • HY-119293
    K777
    1 Publications Verification

    		 Cathepsin CCR Cytochrome P450 Parasite SARS-CoV Filovirus Infection Cancer
    K777 is a potent, orally active and irreversible cysteine protease inhibitor. K777 is also a potent CYP3A4 inhibitor with an IC50 of 60 nM and a selective CCR4 antagonist featuring the potent chemotaxis inhibition. K777 irreversibly inhibits Cruzain, the major cysteine protease of Trypansoma cruzi, and cathepsins B and L. K777 is a broad-spectrum antiviral by targeting cathepsin-mediated cell entry. K777 inhibits SARS-CoV and EBOV pseudovirus entry with IC50 values of 0.68 nM and 0.87 nM, respectively .
    K777
  • HY-N6734
    K-252b

    		PKC Infection
    K-252b, an indolocarbazole isolated from the actinomycete Nocardiopsis, is a PKC inhibitor. K-252b can be used to inhibit extracellular kinases of cells in culture because it can’t pass through cell membrane freely .
    K-252b
  • HY-117010
    Kushenol K

    		Cytochrome P450 HSV SGLT Infection Metabolic Disease
    Kushenol K, a flavonoid antioxidant isolated from the roots of Sophora flavescens. Kushenol K is a cytochrome P-450 3A4 (CYP3A4) inhibitor with a Ki value of 1.35 μM . Kushenol K shows weak antiviral activity against HSV-2 (EC50 of 147 μM) . Kushenol K also inhibits the activity of SGLT1 and SGLT2 .
    Kushenol K
  • HY-115907
    K20

    		Ras ERK Apoptosis Cancer
    K20 is a potent and selective KRas G12C inhibitor with an IC50 of 1.16 µM. K20 shows anticancer activity in H358 cells (IC50= 0.78 µM). K20 decreases the levels of phosphorylated Erk and leads to cancer cell apoptosis. K20 suppresses NCI-H358 tumor growth with a TGI of 41% without causing obvious toxicity .
    K20
  • HY-15779
    K145

    		SphK Apoptosis Cancer
    K145 is a selective, substrate-competitive and orally active SphK2 inhibitor with an IC50 of 4.3 µM and a Ki of 6.4 µM. K145 is inactive against SphK1 and other protein kinases. K145 induces cell apoptosis and has potently antitumor activity .
    K145
  • HY-15779A
    K145 hydrochloride
    5+ Cited Publications

    		 SphK Apoptosis Cancer
    K145 hydrochloride is a selective, substrate-competitive and orally active SphK2 inhibitor with an IC50 of 4.3 μM and a Ki of 6.4 μM. K145 hydrochloride is inactive against SphK1 and other protein kinases. K145 hydrochloride induces cell apoptosis and has potently antitumor activity .
    K145 hydrochloride
  • HY-148013
    K284-6111

    		Beta-secretase NF-κB Neurological Disease
    K284-6111 is an orally active inhibitor for protein chitinase 3-like 1 (CHI3L1). K284-6111 reduces the expression of inflammatory proteins such as iNOS, COX-2, GFAP, and Iba-1, inhibits β-secretase and NF-κB, and suppresses Aβ production. K284-6111 ameliorates the Aβ1–42-induced mice memory impairment, and can be used in research about Alzheimer’s Diseases .
    K284-6111
  • HY-115906
    K783-0308

    		FLT3 MNK Apoptosis Cancer
    K783-0308 is a potent and selective dual inhibitor of FLT3 and MNK2 with IC50 values of 680 and 406 nM, respectively. K783-0308 inhibits the growth of MOLM-13 (IC50=10.5 µM) and MV-4-11 (IC50=10.4 µM) cells. K783-0308 promotes acute myeloid leukemia (AML) cell apoptosis and cell cycle arrests in the G0/G1 phase .
    K783-0308
  • HY-100400A
    K-604 dihydrochloride
    5 Publications Verification

    		 Acyltransferase Cardiovascular Disease
    K-604 dihydrochloride is a potent and selective acyl-CoA:cholesterol acyltransferase 1 (ACAT-1) inhibitor with an IC50 of 0.45±0.06 μM.
    K-604 dihydrochloride
  • HY-U00422
    K-756
    2 Publications Verification

    		 PARP Cancer
    K-756 is a direct and selective tankyrase (TNKS) inhibitor, which inhibits the ADP-ribosylation activity of TNKS1 and TNKS2 with IC50s of 31 and 36 nM, respectively.
    K-756
  • HY-170519
    K13787

    		Bacterial Infection
    K13787 is an acetohydroxyacid synthase (AHAS) inhibitor with antibacterial activity. K13787 has antibacterial activity against a variety of nontuberculous mycobacteria (NTM) and clarithromycin (CLR) resistant strains .
    K13787
  • HY-120943
    K-111

    BM 17.0744

    		 PPAR Metabolic Disease
    K-111 (BM-170744) is an oral active PPAR alpha agonist. K-111 show efficacy in improving insulin resistance, reducing body weight, and ameliorating atherogenic dyslipidemia. K-111 can be used for study of type 2 diabetes, dyslipidaemia, obesity and the metabolic syndrome .
    K-111
  • HY-15685
    Ripasudil
    5+ Cited Publications

    K-115

    		 ROCK Cardiovascular Disease Neurological Disease
    Ripasudil (K-115) is a specific inhibitor of ROCK, with IC50s of 19 and 51 nM for ROCK2 and ROCK1, respectively.
    Ripasudil
  • HY-155284
    K1833

    		Cholinesterase (ChE) Neurological Disease
    K1833 is a hrAChE inhibitor/reactivator, with an IC50 of 58 μM. K1833 also shows high inhibition (IC50=0.57μM) and low reactivation for hrBChE .
    K1833
  • HY-103470
    K114

    		Fluorescent Dye Others
    K114, a fluorescent Congo Red analogue, binds tightly to amyloid fibrils with an EC50 of 20-30 nM . K114 is an efficient detector of semen-derived enhancer of virus infection (SEVI) .
    K114
  • HY-115690
    K-TMZ

    		Drug Derivative Cancer
    K-TMZ is a derivative of methyl ketone, which exhibits antitumor efficacy against O 6 -methylguanine DNA methyltransferase (MGMT) deficient cell. K-TMZ can be used for research of glioblastoma .
    K-TMZ
  • HY-164749
    K-Ras-IN-4

    		Ras Cancer
    K-Ras-IN-4 (compund CP163) is a K-Ras inhibitor .
    K-Ras-IN-4
  • HY-18674
    K-Ras-IN-1

    		Ras Cancer
    K-Ras-IN-1 is the inhibitor for K-Ras by occupying the binding site of son of sevenless (Sos), preventing the interaction between Sos and K-Ras, inhibiting the Sos-catalyzed GDP to GTP exchange process. K-Ras-IN-1 is promising for research of pancreatic, colon and lung cancer .
    K-Ras-IN-1
  • HY-120286
    K-13

    		Drug Intermediate Others
    K-13 is a cyclic peptide compound synthesized by a specific organozinc reagent. Its synthesis process involves intermolecular and intramolecular Negishi cross-coupling reactions and is one of the shortest routes reported for the synthesis of such cyclic peptides.
    K-13
  • HY-150124
    K34c

    		Integrin Cancer
    K34c is a potent and selective α5β1 integrin antagonist. K34c can be used for glioblastoma research .
    K34c
  • HY-U00458
    K-80003
    1 Publications Verification

    TX-803

    		 Akt Cancer
    K-80003 is a potent inhibitor of tRXRα-dependent Akt activation and cancer cell growth.
    K-80003
  • HY-124042
    K6PC-5
    1 Publications Verification

    		 SphK Filovirus Infection Neurological Disease Inflammation/Immunology
    K6PC-5, a ceramide derivative, is a sphingosine kinase 1(SPHK1) activator and elicites a rapid transient increase in intracellular calcium levels. K6PC-5 has the potential for skin diseases involving abnormal keratinocyte, and neurodegeneration and virus infection research .
    K6PC-5
  • HY-111126
    K67
    1 Publications Verification

    		 p62 Keap1-Nrf2 Cancer
    K67 is a selective the interaction between Keap1 and S349 phosphorylated p62 inhibitor, with an IC50 of 1.5 μM. K67 has a weaker inhibitory effect on the interaction between Keap1 and Nrf2 (IC50 is 6.2 μM). K67 competitively binds to the binding site of Keap1 with p-p62, blocking the abnormal activation of the p62-dependent Nrf2 pathway. K67 inhibits tumor cell proliferation and enhances the sensitivity of hepatocellular carcinoma (HCC) to chemotherapeutic drugs by restoring Keap1-mediated ubiquitination and degradation of Nrf2 .
    K67
  • HY-N11463
    Kuwanon K

    		Others Others
    Kuwanon K is a natural product that can be isolated from Morus Lhou .
    Kuwanon K
  • HY-156363
    K-Ras-IN-2

    		Ras Cancer
    K-Ras-IN-2 (Compound CHI-000-667) is a K-Ras antagonist, and can be used for tumor research .
    K-Ras-IN-2
  • HY-P1106
    K41498

    		CRFR Cardiovascular Disease
    K41498 is a potent and highly selective CRF2 receptor antagonist with Ki values of 0.66 nM, 0.62 nM and 425 nM for human CRF2α, CRF2β and CRF1 receptors respectively. K41498 is an analogues of antisauvagine-30 (aSvg-30), inhibits sauvagine-stimulated cAMP accumulation in hCRF2α- and hCRF2β-expressing cells. K41498 can be used for hypotension study .
    K41498
  • HY-B0283A
    Acipimox sodium

    K-9321 sodium

    		 Carbonic Anhydrase Metabolic Disease
    Acipimox (K-9321) sodium, a nicotinic acid analogue, is an antilipolytic compound. Acipimox sodium stimulates leptin releas, inhibits lipolysis and suppresses systemic levels of free fatty acids (FFAs) and improves insulin sensitivity .
    Acipimox sodium
  • HY-B0283
    Acipimox
    1 Publications Verification

    K-9321

    		 Carbonic Anhydrase Metabolic Disease
    Acipimox (K-9321), a nicotinic acid analogue, is an antilipolytic compound. Acipimox stimulates leptin releas, inhibits lipolysis and suppresses systemic levels of free fatty acids (FFAs) and improves insulin sensitivity .
    Acipimox

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: